Alexey Larionov

List of Publications by Year
in descending order

62 papers	3,519 citations	279798 23 h-index	254184 43 g-index
66 all docs	66 docs citations	66 times ranked	6462 citing authors

#	Article	IF	Citations
1	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13820-13825.	7.1	1,257
2	A standard curve based method for relative real time PCR data processing. BMC Bioinformatics, 2005, 6, 62.	2.6	780
3	Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer, 2005, 5, 113.	2.6	125
4	Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Research, 2007, 9, R37.	5.0	109
5	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2270-2278.	1.6	96
6	Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics, 2007, 17, 813-826.	1.5	94
7	Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole. Journal of Clinical Oncology, 2009, 27, 1382-1387.	1.6	93
8	The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene, 2010, 29, 4838-4847.	5.9	87
9	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology and Hepatology, 2018, 3, 489-498.	8.1	87
10	Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Research, 2012, 14, 201.	5.0	76
11	Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Research, 2010, 12, R52.	5.0	72
12	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 2018, 8, 89.	2.8	64
13	High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. International Journal of Cancer, 2012, 130, 2867-2873.	5.1	58
14	Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis. BMC Medical Genomics, 2012, 5, 35.	1.5	53
15	Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 105, 161-165.	1.1	51
16	Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics Journal, 2012, 12, 10-21.	2.0	50
17	Aromatase in skeletal muscle. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 485-492.	2.5	46
18	Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research, 2014, 74, 5371-5376.	0.9	34

#	Article	IF	Citations
19	Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 57-64.	2.5	31
20	High prevalence of<i>GPRC5A</i>germline mutations in<i>BRCA1</i>-mutant breast cancer patients. International Journal of Cancer, 2014, 134, 2352-2358.	5.1	31
21	Aromatase in breast cancer tissue ? localization and relationship with reproductive status of patients. Journal of Cancer Research and Clinical Oncology, 1996, 122, 495-498.	2.5	26
22	Predicting response and resistance to endocrine therapy. Cancer, 2008, 112, 689-694.	4.1	25
23	Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncology, 2009, 5, 1415-1428.	2.4	25
24	Aromatase inhibitorsâ€”Gene discovery. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 130-142.	2.5	24
25	Aromatase inhibitors: Cellular and molecular effects. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 83-89.	2.5	21
26	Molecular effects of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology, 2011, 340, 127-136.	3.2	13
27	Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. Familial Cancer, 2013, 12, 129-132.	1.9	13
28	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Human Molecular Genetics, 2022, 31, 3001-3011.	2.9	9
29	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 2015, 17, 35.	5.0	8
30	Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears. Journal of Cancer Research and Clinical Oncology, 2002, 128, 173-176.	2.5	7
31	Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione. , 1998, 77, 485-487.		6
32	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 228-235.	2.5	6
33	S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.. , 2011, , .		6
34	Bridging the Gap Between Translational Research and Clinical Application. Journal of the National Cancer Institute Monographs, 2011, 2011, 134-137.	2.1	5
35	Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause RareÂSweat Duct Proliferations and Irregular ElastinÂAggregations. Journal of Investigative Dermatology, 2019, 139, 2238-2241.e6.	0.7	5
36	Resistance to Aromatase Inhibitors in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , .	0.1	4

#	Article	IF	Citations
37	Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wildâ€type <i>TP53</i> and mutant <i>KRAS, G3BP1</i> and <i>IL7R</i>. Pediatric Blood and Cancer, 2020, 67, e28354.	1.5	4
38	Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology, 2015, 11, 1301-1305.	2.4	3
39	Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. Journal of Clinical Oncology, 2005, 23, 3025-3025.	1.6	3
40	Androstenedione conversion in human peripheral blood lymphocytes. Bulletin of Experimental Biology and Medicine, 1994, 117, 516-518.	0.8	2
41	Use of Microarray Analysis to Investigate EMT Gene Signatures. Methods in Molecular Biology, 2013, 1046, 85-95.	0.9	2
42	Prediction of Response to Aromatase Inhibitors in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 191-228.	0.1	1
43	PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas. ESMO Open, 2018, 3, A250.	4.5	1
44	Activity of aromatase in breast cancer tissue: Role of the cell substrate. Bulletin of Experimental Biology and Medicine, 1995, 120, 1042-1045.	0.8	0
45	Tumor lymphocytic infiltration, hormonal-metabolic status and aromatase gene expression in breast cancer. European Journal of Cancer, 1997, 33, S10.	2.8	0
46	Androstenedione conversion in lymphocytes infiltrating breast tumor tissue. Bulletin of Experimental Biology and Medicine, 1997, 124, 1008-1010.	0.8	0
47	Androstenedione (A) conversion in lymphocytes infiltrating breast cancer (BC) tissue. European Journal of Cancer, 1998, 34, S83-S84.	2.8	0
48	Expression of the genes of adenylate cyclase (AC) G-protein subunits in breast cancer (BC) tissue: connection with estrogen-dependency?. European Journal of Cancer, 1999, 35, S201.	2.8	0
49	C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target. Breast Cancer Research, 2008, 10, .	5.0	0
50	Molecular Changes in Lobular Breast Cancers in Response to Neoadjuvant Letrozole. Annals of Oncology, 2014, 25, i5.	1.2	0
51	7LBA A 4 gene model can identify ER+HER2+ breast cancers unlikely to respond to neoadjuvant endocrine therapy. European Journal of Cancer, 2014, 50, S3.	2.8	0
52	Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine Oncology, 2021, 1, 33-44.	0.4	0
53	miRNA Profiling of Endocrine-Resistant Breast Tumours.. , 2009, , .		0
54	Gene Expression Profiles of Endocrine Resistant Breast Tumours.. , 2009, , .		0

#	Article	IF	Citations
55	Abstract P4-02-02: Epidermal Growth Factor Receptors (ErbB/HER) and the Ligand Neuregulin 1 (NRG1) Increase in Breast Tumors during Short Time Endocrine Treatment. , 2010, , .		0
56	Abstract P4-02-03: Gene Copy Number Alterations Related to mRNA and miRNA Expression in Endocrine Resistant Breast Cancers. , 2010, , .		0
57	Abstract P6-04-10: Comprehensive gene and protein assessment of the role of Her2 in the response to neoadjuvant Letrozole suggests patients without amplification may also benefit from anti-Her2 treatment. , 2012, , .		0
58	Abstract P6-04-09: Lack of response to aromatase inhibitors involves distinct mechanisms. , 2012, , .		0
59	Abstract P3-06-23: Predicting response to neoadjuvant letrozole. , 2012, , .		0
60	Abstract PD3-2: Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment. , 2013, , .		0
61	Abstract P5-09-01: Comprehensive gene assessment of estrogen receptor positive breast cancer reveals that HER2 plays an important role in resistance to neoadjuvant letrozole. , 2013, , .		0
62	Novel Translational Research of Neo-adjuvant Endocrine Therapy. , 2016, , 189-216.		0